Gene therapy for geographic atrophy in age-related macular degeneration: current insights
Eye · 2025-02 · 39 (2) · 274-283
DOI: 10.1038/s41433-024-03463-w ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Eye, online erschienen am 22.11.2024. Verfasst von Muhammad Usman Jamil und 1 weiteren Autor:innen. Beteiligte Einrichtung: New England Eye Center, Tufts Medical Center, Boston, MA, 02116, USA. Hauptthemen laut MEDLINE: Geographic Atrophy, Genetic Therapy, Macular Degeneration. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Geographic atrophy (GA) is the advanced stage of non-neovascular (dry) age-related macular degeneration, defined by the presence of sharply demarcated atrophic lesions of the outer retina. The complement system is integral to the body's natural immune response, and hence its overactivation can lead to tissue damage and inflammation. It has been shown to play a significant role in GA lesion development and progression, and therefore, complement inhibition is emerging as a promising avenue for therapeutic intervention. With the recent approval by the Food and Drug Administration of drugs like SYFOVRE™ (pegcetacoplan injection) and IZERVAY™ (avacincaptad pegol intravitreal solution), there is hope for the development of interventions capable of slowing down or arresting the progression of GA. In particular, gene therapy intervention is gaining traction for halting GA atrophy at the source of our genes. The concept is to insert a gene into the eye that will act as an ocular "bio-factory," producing a desired protein. This can either lead to overproduction of an already available protein or produce a substance not typically generated in the eye. This review aims to provide an overview of the present understanding of GA, encompassing risk factors, prevalence, pathophysiology, and genetic associations. It will also highlight the current landscape of GA treatment, with particular emphasis on gene therapy intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- New England Eye Center, Tufts Medical Center, Boston, MA, 02116, USA.
- New England Eye Center, Tufts Medical Center, Boston, MA, 02116, USA. nadiakwaheed@gmail.com.
ORCID-Profile: Muhammad Usman Jamil, Nadia K Waheed
Zitieren
APA
Jamil, M. U., & Waheed, N. K. (2025). Gene therapy for geographic atrophy in age-related macular degeneration: current insights. Eye, 39(2), 274-283. https://doi.org/10.1038/s41433-024-03463-w
Vancouver
Jamil MU, Waheed NK. Gene therapy for geographic atrophy in age-related macular degeneration: current insights. Eye. 2025;39(2):274-283. doi:10.1038/s41433-024-03463-w
BibTeX
@article{Jamil2025,
author = {Jamil, Muhammad Usman and Waheed, Nadia K},
title = {Gene therapy for geographic atrophy in age-related macular degeneration: current insights},
journal = {Eye},
year = {2025},
volume = {39},
number = {2},
pages = {274--283},
doi = {10.1038/s41433-024-03463-w}
}
EUVIMED